Please login to the form below

systemic lupus erythematosus

This page shows the latest systemic lupus erythematosus news and features for those working in and with pharma, biotech and healthcare.

in infancy (SAVI) and a subset of systemic lupus erythematosus (SLE).

Biogen scores mid-stage trial win for lupus drug BIIB059

Last approved treatment for Lupus was GSK's Benlysta in 2011. Biogen’s experimental drug for systemic lupus erythematosus (SLE) has hit the mark in a phase 2 trial, adding to ... BIIB059 hit all its objectives in the LILAC study, including a
Second TULIP trial resurrects AZ’s lupus drug anifrolumab

Will now decide whether to file treatment for approval. A year ago, prospects for AstraZeneca’s systemic lupus erythematosus treatment anifrolumab were being written off. ... Lupus is a disease in which the immune system attacks normal cells and tissues
New data backs Merck’s segue into MS with BTK inhibitor

That mechanism also forms the basis of Merck’s testing of evobrutinib in rheumatoid arthritis and systemic lupus erythematosus (SLE), also at the phase 2 stage.
BMS psoriasis drug hits the mark in phase II

BMS also has phase II studies of the drug ongoing in other indications including systemic lupus erythematosus and Crohn's disease.
AstraZeneca’s Lupus treatment misses mark in trial

lupus erythematosus (SLE). ... control. The result of this trial is disappointing for patients and the lupus community.”.

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Rethinking trials: the pros and cons of protocol amendments

A protocol change can work wonders – just ask AstraZeneca. In August, AstraZeneca’s systemic lupus erythematosus candidate anifrolumab achieved the primary efficacy endpoint in an amended trial called Tulip-2. ... Systemic lupus erythematosus is a
Pharma deals during September 2012

In a similar vein, Biogen Idec has sold its royalty rights to Benlysta (belimunab) for the treatment of systemic lupus erythematosus, to DRI Capital Managed Fund. ... Royalty monetisation. Benlysta (belimunab) for the treatment of systemic lupus

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Santhera CEO Klaus Schollmeier joins SuppreMol

This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Add my company

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward: ...
Can eLearning improve patient recruitment and retention?: Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
How Far Do You Want To Go?: Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...